Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares: 2014-2025

Historic Treasury Shares for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $9.9 million.

  • Iovance Biotherapeutics' Treasury Shares fell 0.31% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 0.31%. This contributed to the annual value of $9.5 million for FY2024, which is 176.43% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Treasury Shares stood at $9.9 million, which was down 13.38% from $11.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Treasury Shares' 5-year high stood at $12.2 million during Q1 2025, with a 5-year trough of $3.5 million in Q4 2023.
  • Moreover, its 3-year median value for Treasury Shares was $9.9 million (2025), whereas its average is $8.4 million.
  • In the last 5 years, Iovance Biotherapeutics' Treasury Shares surged by 208.93% in 2024 and then decreased by 3.60% in 2025.
  • Iovance Biotherapeutics' Treasury Shares (Quarterly) stood at $3.5 million in 2023, then surged by 176.43% to $9.5 million in 2024, then decreased by 0.31% to $9.9 million in 2025.
  • Its Treasury Shares was $9.9 million in Q3 2025, compared to $11.4 million in Q2 2025 and $12.2 million in Q1 2025.